AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement.
It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines.
AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the US.
The US accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market - the world's largest, worth $635 billion - before Trump's return to office.
The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes.
Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay.
CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and "equalise" with other countries effectively contributing more to research and development costs.
"The US cannot build or carry the cost of R&D for the entire world," he said.
US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs.
"For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness," said Lutnick in a statement issued by AstraZeneca.
While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any levies take effect.
The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place.
The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said.
The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis and Sanofi.
Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies.
The new Virginia facility - the company's largest single manufacturing investment - will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said.
The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000.
In January it scrapped plans to invest £450m in its vaccine manufacturing plant in northern England, citing a cut in government support.
Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the US. The company declined to comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTÉ News
an hour ago
- RTÉ News
Coca-Cola beats on zero-calorie drinks, higher prices; to launch cane sugar-based drink
Coca-Cola has today beaten estimates for quarterly revenue and profit, benefiting from resilient demand for zero-calorie drinks as well as higher pricing, and laid out plans to launch a new product made with cane sugar in the US this year. Food companies are increasingly lookingto include healthier substitutes as they respond to Health Secretary Robert F Kennedy Jr's Make America Healthy Again campaign. Last week, President Donald Trump said Coca-Cola had agreed to use real cane sugar in the US. While there are some slight differences between cane sugar and corn syrup as sweeteners, experts have said that too much of either is not good for consumers. Coca-Cola already sells Coke made from cane sugar in other markets, including Mexico, and some US grocery stores carry glass bottles with cane sugar labeled "Mexican" Coke. The switch to cane sugar will also drive up costs for the company, industry analysts have said. Changes in the formulation of the rest of the Coke sold in the US, and other beverages and candies, would involve significant adjustments to supply chains. Rival PepsiCo, which topped quarterly earnings estimates last week, also said it would use natural ingredients in its products if consumers want it. Coca-Cola reiterated that the hit to costs due to "global trade dynamics" remained manageable. The company has said it would look at affordable packaging options such as plastic bottles when Trump imposed a 25% duty on aluminum imports. As of June, tariffs on aluminum imports have doubled to 50%. Coca-Cola's comparable revenue rose 2.5% to $12.62 billion in the second quarter, beating estimates of $12.54 billion, according to data compiled by LSEG. Annual comparable earnings per share is expected to be near the top end of its target of a 2% to 3% rise, helped by a weaker dollar. Volumes fell in North America "due to the continued uncertainty and pressure on some socioeconomic segments of consumers," CEO James Quincey said on a post-earnings call. Demand for pricey fizzy drinks has remained choppy in recent quarters, especially in developed countries as consumers, especially in lower-income segments, turned more price-sensitive. Coca-Cola's volumes slipped 1% in the three months ended June 27 after rising 2% each in the previous two quarters, largely due to declines in key markets such as Mexico and India, as well as for its Coca-Cola brand in the US. Quincey added that a boycott-related hit to demand in the US and Mexico was now largely resolved. Volumes had fallen in the first half of the year in North America due to Hispanic consumers in the US and Mexico boycotting the company's legacy brands after a viral video of Coca-Cola laying off Latino staff and reporting them to Immigration and Customs Enforcement. Prices rose 6% overall in the second quarter, led by increases in some inflationary markets. Coca-Cola's shares have risen 12.5% this year, as of yesterday's close. Coca-Cola Zero Sugar volume jumped 14%, driven by growth across all geographies, and was a bright spot in the quarter.
Irish Times
an hour ago
- Irish Times
Top Republican Mike Johnson shuts US Congress early to avoid Epstein vote
The Republican speaker of the US House of Representatives will send members of Congress home early to avoid a vote on releasing files relating to Jeffrey Epstein , as Donald Trump 's allies seek to contain a spiralling crisis over the administration's handling of the case. The House of Representatives is set to be in recess from Wednesday for five weeks, a day earlier than scheduled, and is not expected to return until September. Mr Johnson said on Tuesday that Democrats were playing 'political games' by trying to force votes on measures that would require the US Department of Justice to release documents relating to the life and death of the disgraced financier. Several Republican House members have also called for the so-called 'Epstein files' to be made public, as some of the loudest voices in Trump's Maga movement have demanded greater transparency. READ MORE A memo by the DoJ and FBI this month stated there was no 'credible evidence' that the disgraced financier 'blackmailed prominent individuals as part of his actions' and that an Epstein 'client list' did not exist. The furore was fuelled last week when the Wall Street Journal reported that Mr Trump had sent Epstein a birthday message in 2003 that referred to 'secrets' and contained a lewd drawing. Mr Trump has since sued the newspaper and its owner Rupert Murdoch , alleging libel and demanding $10 billion in damages. But as he moved for an early recess on Tuesday, Mr Johnson pinned the blame on the opposition, saying Democrats were using the Epstein case as a 'political battering ram'. 'We're not going to allow them to engage in that charade any more,' Mr Johnson said at a news conference. 'We're done being lectured on transparency.' He complained about 'endless efforts to politicise the Epstein investigation'. 'We're not going to play political games with this,' he said, wrapping up his final news conference before September. [ Lack of Epstein 'client list' testing Maga Republicans' faith in Trump to the limits Opens in new window ] After initially saying the material should come out, Mr Johnson on Monday vowed that he would not schedule a vote this summer on whether to release the Epstein files, saying that Mr Trump needed 'space' to determine how to proceed. On Tuesday he said Republicans were united on the issue. Mr Johnson's intervention came as Mr Trump and his allies seek to stamp out criticism of his administration's handling of the Epstein case. A top Department of Justice official earlier on Tuesday said he would meet Ghislaine Maxwell, who was convicted for helping lure underage girls for Epstein, for possible evidence. 'If Ghislaine Maxwell has information about anyone who has committed crimes against victims, the FBI and the DoJ will hear what she has to say,' deputy attorney-general Todd Blanche said. He said he had contacted the lawyer for Maxwell, who is serving a 20-year prison sentence and intended 'to meet with her soon'. Mr Trump has repeatedly railed against public interest in the case in recent weeks. But asked about Mr Blanche's intervention on Tuesday, Mr Trump told reporters in the Oval Office: 'I didn't know that they were going to do it. I don't really follow that too much ... It's a witch-hunt, just a continuation of a witch-hunt.' Republicans had planned votes this week on an immigration measure, a permitting Bill and a rollback of some Biden-era regulations. But the House Rules Committee, the powerful panel controlled by the speaker that determines which legislation reaches the floor, has been upended by the Epstein issue, with Democrats repeatedly demanding votes on it. Democrats on the committee vowed to force such a vote again this week as part of a routine measure to allow debate on unrelated legislation. But Republicans did not want to go on the record on the matter, for fear of retribution from angry supporters who are demanding the release of the Epstein files. The result is that the house cannot move ahead on any substantive legislation. Republicans now plan to wrap up votes on Tuesday and early Wednesday on some non-controversial Bills and call their recess by midafternoon on Wednesday. – Copyright The Financial Times Limited 2025
Irish Daily Star
an hour ago
- Irish Daily Star
12 times Trump's fake tan has looked horrible and exposed shocking reality
Donald Trump's skin tone has been a topic of intrigue for years, and the curiosity surrounding his unique hue doesn't seem to be fading anytime soon Donald Trump's signature "orange hue" has long been a source of fascination, and the intrigue about his distinctive skin tone shows no signs of waning. The former US president is notorious for his glowing complexion, but it wasn't always so. Observers note that Trump's tanning booth-kissed appearance became a staple only after 2012, during his time on The Apprentice, when he began to apply makeup more frequently for TV appearances and public engagements. From then on, his orange tint became a hallmark, and by 2015, as he stepped into the political arena as a presidential hopeful, the world took a keen interest in his tanning practices. There's been plenty of speculation over the years about how Trump achieves his "orange" look. 'Fake Melania' theory sparked as critics spot four signs after odd sunglasses and cap Donald Trump's 7-word quip to Speaker Mike Johnson about his wife Experts agree that at times, Trump's artificial tan appears particularly vivid, with the orange intensity peaking in 2020, only to be toned down as the 2024 election approaches. A notably poor photo from 2020 even sparked a scientific investigation. Researchers have concluded that Trump's fluctuating skin color is likely due to self-tanner rather than heavy makeup application. A PubMed study titled 'Fake tan or fake news?' delved into the distinctive skin tone of Donald Trump, comparing it to natural and artificial tanning ranges. "We then compared the estimated skin colours with two existing data sets of skin colours: the range of skin tans that occur naturally in the Caucasian population and the range skin colors brought about by a sunless tan. We find that Trump's skin color is close to the edge of the natural skin tan gamut and firmly within the gamut of a sunless skin tan," the study reported. The lighter area around his eyes has been attributed by some to wearing protective goggles while tanning. Despite this analysis, Trump's camp has consistently denied using spray tans or sunbeds. In 2019, an anonymous White House insider claimed to The New York Times, under strict anonymity, that Trump's unique hue was simply due to 'good genes.' Despite his denials, here are 12 times when Trump's tan situation took the internet by surprise. Trump before the tan and makeup Tan peaks in 2020 Pressure on means tanning bed is on Two different skin tones in court
